ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
Fecha
2020Autor
Dong, Mengzhen
Zhang, Jie
Ma, Xuefeng
Tan, Jie
Chen, Lizhen
Liu, Shousheng
Xin, Yongning
Zhuang, Likun
Documentos PDF
Resumen
At the end of 2019, the coronavirus disease 2019 (COVID-19), caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China.
Currently, it is breaking out globally and posing a serious threat to public health. The
typically clinical characteristics of COVID-19 patients were fever and respiratory
symptoms, and a proportion of patients were accompanied by extrapulmonary
symptoms including cardiac injury, kidney injury, liver injury, digestive tract injury,
and neurological symptoms. Angiotensin converting enzyme 2 (ACE2) has been
proven to be a major receptor for SARS-CoV-2 and could mediate virus entry into
cells. And transmembrane protease serine 2 (TMPRSS2) could cleave the spike (S)
protein of SARS-CoV-2, which facilitates the fusion of SARS-CoV-2 and cellular
membranes. The mRNA expressions of both ACE2 and TMPRSS2 were observed in
the heart, digestive tract, liver, kidney, brain and other organs. SARS-CoV-2 may have
a capacity to infect extrapulmonary organs due to the expressions of ACE2 and
TMPRSS2 in the cells and tissues of these organs. It seems that there is a potential
involvement of ACE2 and TMPRSS2 expressions in the virus infection of
extrapulmonary organs and the manifestation of symptoms related to these organs in
patients with COVID-19. Here, we revealed the expressions of ACE2 and TMPRSS2
in extrapulmonary organs, and we also summarized the clinical manifestation and the
management of extrapulmonary complications in patients with COVID-19.
Palabras clave
COVID-19; ACE2; TMPRSS2Enlace al recurso
https://doi.org/10.1016/j.biopha.2020.110678Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.